A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer

Preclinical data have demonstrated that the combination of antihuman epidermal growth factor receptor-2 (anti-HER2) and antivascular endothelial growth factor (anti-VEGF)—targeted agents has antitumor activity; these data indicate certain patients with HER2-overexpressing breast cancer may derive cl...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Rugo, Hope S., Jo Chien, A., Franco, Sandra X., Stopeck, Alison T., Glencer, Alexa, Lahiri, Soumi, Arbushites, Michael C., Scott, Janet, Park, John W., Hudis, Clifford, Nulsen, Ben, Dickler, Maura N.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer US 2011
Soggetti:
Review
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3397213/
https://ncbi.nlm.nih.gov/pubmed/22198412
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-011-1918-z
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi